KCT0008847RecruitingUnknown
Clinical usefulness of virtual antiarrhythmic drug test in patients with recurred AF after catheter ablation (CUVIA-AF3)
Yonsei University Health System, Severance Hospital0 sites300 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Unknown
- Status
- Recruiting
- Enrollment
- 300
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20(Year) to 80(Year) (—)
- Sex
- All
Inclusion Criteria
- •1. The patients with 20~80 years old those recurred AF after catheter ablation
- •2. Patients who are suitable for sinus rhythm conversion and maintenance using AAD medications
- •3. Patients who had no history of serious side effects due to AAD medications before the procedure
Exclusion Criteria
- •1. Permanent AF Patients
- •2. AF associated with significant structural heart disease with severe anomaly or hemodynamic effects
- •3. Patients expected to have serious side effects when using AAD due to sinus node dysfunction
- •4. Severe liver or renal failure
- •5. Patients with past cardiac surgery history
- •6. Patients who are unable to oral medication or have electrolyte abnormalities
- •7. Patients with active internal bleeding
- •8. Contraindications for anticoagulant therapy (administered anticoagulant drugs to prevent cerebral infarction) or AAD
- •9. Valvular AF (mitral stenosis> grade 2, mechanical valve, mitral valve repair)
- •10. Severe concomitant illness
- •11. Patients expected to live for less than one year
- •12. Patients with drug or alcoholism
- •13. Those who cannot read the agreement (literacy, foreigners, etc.)
- •14. Patients judged to be inappropriate for participation in clinical trials by other researchers' judgment
Investigators
Similar Trials
Recruiting
Not Applicable
Clinical Effectiveness of Atrial Anti-tachycardia Pacing Therapy in Sick Sinus Syndrome with Previous Atrial Fibrillation Ablation (CEASE-AF)Sick sinus syndromeCardiovascular - Other cardiovascular diseasesAtrial FibrillationACTRN12616001353482Centre for Heart Rhythm Disorders, University of Adelaide, Royal Adelaide Hospital136
Not yet recruiting
Phase 1
Antiarrhythmic effects of phenytoin or dantrolene in patients with cardiomyopathy.ArrhythmiaCardiomyopathyACTRN12619000730101niversity of Newcastle105
Active, not recruiting
Phase 1
Evaluation of the anti-arrhythmic effects of 3 oral dosages of S 44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia. A 12-week, randomized, double-blind, parallel-group, placebo controlled, international multicentre study.EUCTR2009-014940-12-FRInstitut de Recherches Internationales Servier160
Completed
Phase 2
Evaluation of the anti-arrhythmic effects of 3 dosages of S 44121 versus placebo in patients with chronic heart failure at risk for ventricular arrhythmiaCardiac arrhythmia in chronic heart failureCirculatory SystemOther cardiac arrhythmiasISRCTN14227980Institut de Recherches Internationales Servier (France)149
Active, not recruiting
Phase 1
Evaluation of the anti-arrhythmic effects of 3 oral dosages of S 44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia. A 12-week, randomized, double-blind, parallel-group, placebo controlled, international multicentre study.Chronic Heart Failure and left ventricular systolic dysfunction at risk for ventricular arrhythmiaMedDRA version: 12.1Level: LLTClassification code 10007558Term: Cardiac failure chronicMedDRA version: 12.1Level: LLTClassification code 10049694Term: Left ventricular dysfunctionMedDRA version: 12.1Level: LLTClassification code 10047281Term: Ventricular arrhythmiaEUCTR2009-014940-12-HUInstitut de Recherches Internationales Servier160